Effect of haloperidol decanoate on the cardiovascular system.
Rapid speed electrocardiograms were recorded in 13 chronic schizophrenic patients before, and at regular intervals during a six-month trial of haloperidol decanoate. Measurements of conduction intervals in the EEG were carried out blind to patient and to assessment interval. No significant changes in heart rate; PR, QRS on QTc intervals; or T-wave height were found. Neither was there a significant change in the blood pressure. The findings confirm that haloperidol does not have clinically relevant cardiac effects when given in therapeutic doses to physically healthy individuals.
Kaneko
S
S
Department of Neuropsychiatry, Hirosaki University School of Medicine, Japan.
Edwards
J G
JG
Goldie
A
A
Fukushima
Y
Y
Sato
T
T
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; C033563:haloperidol decanoate; D006220:Haloperidol